Litigation Details for ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2025)

« Back to Dashboard

ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2025)

Docket		Date Filed	2025-08-15
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Karen M. Williams
Jury Demand	None	Referred To	Ann Marie Donio
Parties	ALKERMES, INC.
Patents	11,707,466; 11,951,111
Attorneys	CHARLES MICHAEL LIZZA
Firms	Greenberg Traurig, LLP
Link to Docket	External link to docket

Details for ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-08-15				External link to document

Litigation Summary and Analysis: Alkermes, Inc. v. Teva Pharmaceuticals, Inc. (D.N.J. 1:25-cv-14685)

Last updated: August 1, 2026

ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC., Case No. 1:25-cv-14685 (filed 2025) is a Hatch-Waxman patent infringement action asserting infringement of drug patents tied to an FDA-approved product and seeking relief under 35 U.S.C. § 271(e)(2) based on Teva’s ANDA-type submission. The case is at an early procedural stage with no dispositive rulings reflected in the public docket information available here.

Core actionable point for business teams: until the asserted patent list, Orange Book tie, and the specific Paragraph IV certifications are identified from the complaint and exhibits, the infringement scope, claim construction risk, and settlement leverage cannot be quantified with patent-by-patent specificity.

What does Alkermes v. Teva 1:25-cv-14685 allege and what patents are asserted?

Featured snippet answer: A § 271(e)(2) Hatch-Waxman infringement suit brought by Alkermes against Teva, tied to an FDA regulatory submission for an ANDA that implicates specific Orange Book patents listed for the relevant reference listed drug.

What court and procedural posture controls leverage

• Case: Alkermes, Inc. v. Teva Pharmaceuticals, Inc.
• Docket: 1:25-cv-14685
• Statutory vehicle: 35 U.S.C. § 271(e)(2) (Hatch-Waxman “substantial step” theory for patent infringement based on FDA application submission).
• Likely filing contents (typical in these cases):
  • Complaint alleging infringement of one or more Orange Book-listed patents.
  • Exhibit(s) describing Teva’s FDA submission and certifications (Paragraph IV/IV carve-outs).
  • Requested remedies (injunction against FDA approval and damages to the extent pled).

Which “thing to measure” for litigation strength

Litigation outcomes in this category depend on four items that normally come from the complaint:

1. Asserted patent set (utility, formulation, method-of-use, polymorph, manufacturing).
2. Claims-in-suit and their dependency on drug substance vs. finished form.
3. Teva’s regulatory submission linkage (the ANDA-to-RLD match, including strengths and dosage forms).
4. Teva’s defenses (non-infringement, invalidity under § 102/103/112 or inequitable conduct, and prosecution-history estoppel where applicable).

Public docket snapshots without the complaint text do not provide those four inputs in a way that allows a reliable patent-by-patent infringement and validity analysis.

When does exclusivity end for the product at issue, and when does each asserted patent expire?

Featured snippet answer: Exclusivity and patent expiry dates are product- and patent-specific. Without the asserted patent numbers and the FDA listing that ties them to Teva’s ANDA, an exclusivity/patent timeline cannot be constructed accurately for this case.

What you need to map in this case (and why it drives settlement)

In Hatch-Waxman, business and litigation teams build a tight timeline:

• Regulatory exclusivity (e.g., 3-year, 5-year, and pediatric exclusivity where relevant).
• Orange Book patent expirations (base patents, later-intended patents, formulation/manufacturing patents).
• Delays from litigation:
  • 30-month stay triggered by Paragraph IV notice and timing under 21 U.S.C. § 355(j)(5)(B)(iii).
  • Any eventual settlement that converts litigation into an earlier-than-otherwise generic launch date.

Because the asserted patent list and the RLD match are not available in the information provided here, any expiration or exclusivity dates would be speculative and not suitable for litigation decision-making.

Is Teva’s ANDA challenge framed as Paragraph IV, and what certification triggers the case?

Featured snippet answer: Hatch-Waxman infringement suits like this one typically proceed on a Paragraph IV certification tied to specific Orange Book patents. The exact certification text and which patents were challenged are complaint-dependent and are not present in the limited information available here.

Why Paragraph IV scope changes the entire case

Paragraph IV drives:

• The number of patents in suit (often 1 to 10).
• The claim construction contest (composition vs. method vs. formulation).
• The invalidity theories (anticipation/obviousness over specific prior art; § 112 arguments on enablement or written description).
• Settlement economics: the “winning” patent often determines an at-risk date even if others fall.

What is the claim construction and infringement risk in Alkermes v. Teva?

Featured snippet answer: Infringement risk turns on whether Teva’s ANDA product falls within the asserted claims. That analysis requires claim language and Teva’s ANDA technical disclosures, which are typically in the complaint and exhibits and are not available in the information provided here.

Typical high-impact infringement issues in Alkermes-style pharma patent estates

Even without the specific patents here, the highest-frequency claim constructions in Hatch-Waxman for specialty drugs cluster around:

• Composition limitations: drug substance identity, salt form, polymorph, particle size ranges, and excipient composition.
• Formulation structure: controlled-release, extended-release, or depot characteristics defined by parameters.
• Method-of-use constraints: specific dosing regimens, patient populations, or administration routes.
• Manufacturing steps: where formulation patents include process limitations that can be designed around.

A defensible infringement assessment requires the asserted claim elements and Teva’s product characterization.

How do invalidity arguments usually break down in these cases, and how would they apply here?

Featured snippet answer: Invalidity typically targets anticipation/obviousness and asserted written description/enablement defects. Case-specific application requires the asserted patent numbers and their prosecution histories and the prior art cited in the defendant’s filings.

Common invalidity patterns to map once patents are identified

• § 102: single reference anticipation of every element.
• § 103: obviousness combining references and routine optimization arguments.
• § 112(a): lack of adequate written description for claimed ranges or embodiments.
• § 112(b): indefiniteness.
• Prosecution history: disclaimer or narrowing amendments reducing Teva’s design-around ability.

What does the docket show about motions, hearings, and timelines in 1:25-cv-14685?

Featured snippet answer: No merits outcomes are established in the available information here. The docket-level litigation posture is early and motion activity cannot be enumerated without docket entries.

What milestones control forward planning

In these cases, key milestones usually include:

• Motion to dismiss or to stay (less common in early stage once answer filed).
• Claim construction (Markman).
• Summary judgment on invalidity or non-infringement.
• Final pretrial and trial scheduling, or settlement-induced dismissal.

A business-grade forecast requires the schedule, which depends on the actual docket entries.

How strong is Alkermes’ patent estate in this dispute versus Teva’s expected challenges?

Featured snippet answer: Strength is patent- and claim-specific. With the asserted patent numbers and claim charts not provided, no defensible scoring can be generated.

What a “strength score” should include once patents are listed

• Number of independent claims asserted per patent
• Claim breadth (composition vs. parameterized vs. process limitations)
• Family size and geographic coverage
• Litigation history of the same patent family (prior outcomes)
• Reexamination/IVD/terminal disclaimer posture (if any)
• Prior art vulnerability based on claim priority date and disclosure overlap

What generic entry risks exist for Teva and what settlement scenarios typically follow?

Featured snippet answer: Entry risk depends on (i) whether Teva wins invalidity/non-infringement for all asserted patents or (ii) whether a partial settlement grants a “carve-out” date. Without the asserted patent set and any settlement filings, no launch date range can be stated.

Standard settlement levers in Hatch-Waxman

• Dismissal with a stipulated launch date tied to surviving patents.
• Royalty or supply agreements where permitted.
• “Work-share” agreements or field-of-use carve-outs, if relevant.

What is the Orange Book status of the product connected to Alkermes v. Teva?

Featured snippet answer: Orange Book status is determined by the specific reference listed drug and its listed patents. The asserted patent list and the product identity are not present in the information provided here, so an Orange Book-specific inventory cannot be produced.

Which companies are co-defendants or involved in parallel cases for this same patent set?

Featured snippet answer: Parallel cases depend on the defendant set and the product. No co-defendant or related case list is provided in the information available here.

How to identify co-pending matters (once docket content is available)

• Related-case identifiers in the docket.
• Shared patents across ANDA defendants for the same RLD.
• Consolidations or coordinated claim construction among defendants.

How does Alkermes v. Teva compare with other Hatch-Waxman litigations by Alkermes?

Featured snippet answer: Comparative analysis requires:

• The specific Alkermes drug and patent family in this case.
• The other litigations’ asserted patents, outcomes, and injunction history.

Those inputs are not available in the information provided here.

Key Takeaways

• Case type: Hatch-Waxman patent infringement under 35 U.S.C. § 271(e)(2).
• Procedural stage: early, with no merits outcomes stated in the provided information.
• What cannot be reliably quantified from the provided inputs: asserted patent numbers, Orange Book linkage, certification scope (Paragraph IV details), exclusivity and expiry dates, and claim-by-claim infringement/invalidity risk.
• Business action standard: litigation planning for this docket should focus on obtaining and analyzing the complaint’s asserted patent list and Teva’s ANDA linkage to the Orange Book for the RLD.

FAQs

1. What is the typical remedy Alkermes seeks in Hatch-Waxman suits against ANDA filers like Teva?
   Injunctive relief preventing FDA approval of the ANDA prior to patent expiry for claims found infringed, plus damages where pled.

2. How does the 30-month stay work in Paragraph IV cases like this?
   It pauses FDA approval upon a timely Paragraph IV notice, subject to litigation timeline and statutory exceptions.

3. What defenses are most common for ANDA defendants in § 271(e)(2) cases?
   Non-infringement, invalidity under §§ 102/103/112, and sometimes inequitable conduct/prosecution history estoppel.

4. Can a settlement in Alkermes v. Teva change the launch timing for other generic entrants?
   It can indirectly, but the binding effect is typically limited to the settling parties unless other defendants separately agree or are constrained by the surviving patents.

5. Do formulation or method-of-use patents change the design-around strategy for Teva?
   Yes. Formulation parameters and method-of-use steps can be harder to avoid without altering the approved product profile, while manufacturing/process limitations can create additional design-around pathways.

References (APA)

1. Alkermes, Inc. v. Teva Pharmaceuticals, Inc., No. 1:25-cv-14685 (D.N.J. filed 2025). (Case docket).